![[CCO] Certification Coaching Organization LLC](https://staging.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Systemic hypertension (HTN) is a chronic medical condition defined as persistently elevated arterial blood pressure — classically ≥130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline, and ≥140/90 mmHg per older JNC 7 criteria. In ICD-10-CM, there are no BP thresholds or severity descriptors (mild/moderate/severe) embedded in the code structure — the classification hinges entirely on documented causality, organ involvement, and complications. The FY2026 ICD-10-CM Official Guidelines section I.C.9 governs hypertension coding and its presumed causal relationships.
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological state defined as a mean pulmonary arterial pressure (mPAP) >20 mmHg at rest, as updated by the 6th World Symposium on Pulmonary Hypertension (Nice, 2018). The older threshold was ≥25 mmHg. PH encompasses five WHO/Nice diagnostic groups with distinct etiologies, treatments, and ICD-10-CM codes. It is distinct from systemic hypertension and is coded in the I27.x category.
Clinical significance for coders and CDI specialists: Hypertension is the most common chronic condition documented in inpatient and outpatient records. Accurate coding — especially capturing hypertensive heart disease (I11.x), hypertensive CKD (I12.x), and the combination (I13.x) — is essential for proper DRG assignment, risk adjustment, quality measures, and HCC capture under CMS HCC Model v28.
Under CMS HCC Model v28 (effective 2024, fully phased in 2026), I10 Essential (primary) hypertension alone no longer maps to any HCC. In v24, I10 mapped to HCC 85 (approximately $80/patient/year RAF value). Payers and practices lose this RAF value unless downstream complications — hypertensive heart disease (I11.x), hypertensive CKD (I12.x), heart failure (I50.x), CKD stage (N18.x) — are documented and coded. This is arguably the single largest coding change affecting cardiovascular risk adjustment in recent CMS history. Ensure all hypertensive complications are captured with specificity.
🗂️ Alternative Terminology
| Formal / ICD-10-CM Term | Colloquial / Lay / Clinical Synonyms |
|---|---|
| Essential (primary) hypertension (I10) | High blood pressure, HTN, HBP, idiopathic hypertension, benign hypertension (outdated), primary HTN |
| Hypertensive heart disease (I11.x) | Hypertensive cardiomyopathy, HTN heart disease, cardiac hypertension, hypertensive LVH with HF |
| Hypertensive chronic kidney disease (I12.x) | Hypertensive nephropathy, HTN-CKD, hypertensive renal disease, hypertension-related CKD |
| Hypertensive heart and CKD (I13.x) | Cardiorenal hypertension, combined hypertensive HF and renal disease, HTN triad |
| Secondary hypertension (I15.x) | Renovascular HTN, endocrine HTN, secondary HBP, hypertension due to renal artery stenosis |
| Hypertensive urgency (I16.0) | Severe asymptomatic hypertension, BP crisis without end-organ damage, stage 3 HTN (informal) |
| Hypertensive emergency (I16.1) | Malignant hypertension (mostly historical), hypertensive crisis with end-organ damage, accelerated HTN |
| Primary pulmonary arterial hypertension (I27.0) | Idiopathic PAH, primary PH, IPAH, sporadic PAH, Group 1 PAH |
| Secondary pulmonary arterial hypertension (I27.21) | Heritable PAH, drug-induced PAH, CTD-associated PAH, Group 1' PAH |
| PH due to left heart disease (I27.22) | Passive pulmonary hypertension, Group 2 PH, post-capillary PH, pulmonary venous hypertension |
| PH due to lung diseases/hypoxia (I27.23) | Group 3 PH, hypoxic PH, COPD-related PH, ILD-related PH |
| Chronic thromboembolic PH (I27.24) | CTEPH, Group 4 PH, chronic PE with PH, thromboembolic PH |
| Cor pulmonale, chronic (I27.81) | Pulmonary heart disease, right-sided heart failure from lung disease, chronic RV failure |
| Persistent pulmonary hypertension of newborn (P29.3) | PPHN, persistent fetal circulation, neonatal PH |
| Gestational hypertension (O13.x) | Pregnancy-induced HTN, PIH, transient HTN of pregnancy |
| Preeclampsia (O14.x) | Gestational HTN with proteinuria, toxemia (outdated), pre-eclampsia |
| Eclampsia (O15.x) | Toxemia with seizures (outdated), eclamptic convulsions |
🩺 Signs & Symptoms
Systemic Hypertension
Systemic hypertension is frequently asymptomatic and discovered incidentally. When symptomatic, common manifestations include:
- Headache — classically occipital, worse in the morning; may signal hypertensive urgency/emergency
- Epistaxis — nose bleeds associated with elevated BP
- Visual changes — blurred vision, scotoma in hypertensive retinopathy (H35.0, code I10 first)
- Dizziness / lightheadedness
- Palpitations / chest pain — especially with hypertensive heart disease
- Dyspnea — when hypertensive heart failure (I11.0) has developed
- Edema — peripheral or pulmonary when concurrent heart failure or CKD is present
- Hematuria, proteinuria — signs of hypertensive nephropathy (I12.x)
- End-organ damage signs in HTN emergency (I16.1): papilledema, focal neurological deficits, AKI (elevated creatinine), chest pain (AMI/aortic dissection), pulmonary edema
Pulmonary Hypertension
- Dyspnea on exertion — earliest and most common symptom; progresses to dyspnea at rest
- Fatigue and weakness
- Syncope or pre-syncope — exertional, indicates severe PH
- Chest pain — right ventricular angina, often exertional
- Peripheral edema — sign of right heart failure / cor pulmonale (I27.81)
- Cyanosis — in advanced or shunt-related PH (Eisenmenger syndrome I27.83)
- Loud P2 (pulmonary component of S2) on auscultation; right ventricular heave
- Hemoptysis — uncommon; occurs in CTEPH (I27.24) or idiopathic PAH
- Ascites / hepatomegaly — in advanced cor pulmonale with right ventricular failure
Per ICD-10-CM Official Guidelines I.C.18, when a symptom (e.g., headache, dyspnea) is an integral manifestation of an established diagnosis, code only the diagnosis — not the symptom code. If the symptom is separately documented as a distinct clinical problem requiring additional evaluation, it may be coded additionally.
🧭 Differential Diagnosis
| Condition | Key Distinguishing Features | Primary ICD-10-CM Code |
|---|---|---|
| Essential (primary) hypertension | No identifiable secondary cause; most common; diagnosis of exclusion in adults | I10 |
| White coat hypertension | BP elevated only in clinical setting; normal ambulatory BP monitoring (ABPM); use R03.0 if no formal dx | R03.0 / I10 if dx confirmed |
| Secondary — renovascular | Renal artery stenosis (atherosclerosis or FMD); abdominal bruit; difficult to control | I15.0 |
| Secondary — renal parenchymal | CKD, glomerulonephritis, polycystic kidney disease; elevated creatinine | I15.1 |
| Secondary — endocrine | Primary aldosteronism (hypokalemia, adrenal adenoma), Cushing syndrome, pheochromocytoma (paroxysmal HTN, headache, diaphoresis, tachycardia), thyroid disease | I15.2 |
| Secondary — drug-induced | NSAIDs, oral contraceptives, decongestants, stimulants, cocaine, cyclosporine, erythropoietin | I15.8 |
| Hypertensive urgency (I16.0) | BP ≥180/120; no end-organ damage; asymptomatic or mild symptoms | I16.0 |
| Hypertensive emergency (I16.1) | BP ≥180/120 WITH end-organ damage (stroke, AMI, AKI, papilledema, aortic dissection) | I16.1 + EOD code first if applicable |
| Idiopathic PAH (Group 1) | Young women; no identifiable cause; diagnosis after exclusion of other PH groups; right heart cath mPAP ≥20 mmHg | I27.0 |
| PH due to left heart disease (Group 2) | Most common PH; associated with HF with preserved or reduced EF, mitral/aortic valve disease | I27.22 |
| PH due to lung disease/hypoxia (Group 3) | COPD, ILD, obstructive sleep apnea, chronic hypoxemia; often mild PH | I27.23 |
| CTEPH (Group 4) | History of PE; perfusion scan shows mismatched defects; potentially curable with pulmonary endarterectomy | I27.24 |
| Other/multifactorial PH (Group 5) | Sarcoidosis, chronic hemolytic anemia, myeloproliferative disorders, metabolic diseases | I27.29 |
| Cor pulmonale (chronic) | Right ventricular hypertrophy/failure due to chronic lung disease; distinguish from acute cor pulmonale (I26.0x, which is due to acute PE) | I27.81 |
| Gestational hypertension | New-onset HTN after 20 weeks gestation; no proteinuria; resolves postpartum; code O13.x — NOT I10 | O13.x |
| Preeclampsia | HTN + proteinuria ≥300 mg/24h or end-organ damage after 20 weeks; severe features: BP ≥160/110, thrombocytopenia, AKI, impaired liver function, pulmonary edema, new headache | O14.x |
📋 Clinical Indicators for Coders/CDI
| Clinical Indicator | Documentation Needed | Code Consideration |
|---|---|---|
| BP reading ≥130/80 without HTN diagnosis documented | MD must establish diagnosis; elevated BP alone at one visit ≠ HTN diagnosis | R03.0 only (not I10) |
| HTN documented without complications | Provider writes "hypertension," "HTN," or "high blood pressure" as a diagnosis | I10 |
| HTN + cardiac condition (LVH, systolic dysfunction, diastolic dysfunction, HF) | Documentation must link the two conditions causally ("hypertensive heart disease" or "heart disease due to hypertension" or "HF due to HTN"); per Guideline I.A.15 "with" convention | I11.0 (with HF) or I11.9 (without HF) + I50.x type if HF present |
| HTN + CKD of any stage | Both diagnoses documented; Guidelines I.C.9.a.2 PRESUME causal — no explicit link required | I12.x + N18.x (automatic presumption — do NOT use I10 + N18.x) |
| HTN + HF + CKD (triad) | All three documented; combination code I13.x used | I13.x + N18.x stage + I50.x HF type |
| HTN + retinopathy | Hypertensive retinopathy documented | H35.0 with I10 (code I10 first — mandatory "code first" convention) |
| BP ≥180/120 without end-organ damage | No evidence of AKI, stroke, MI, papilledema, aortic dissection | I16.0 (HTN urgency) |
| BP ≥180/120 WITH end-organ damage | Documented acute MI, ICH, stroke, AKI, papilledema, aortic dissection — code the EOD first | I16.1 + specific EOD code(s) |
| PH documented, type unspecified | Physician documents "pulmonary hypertension" without grouping | I27.20; query for group/etiology |
| PAH in context of connective tissue disease (CTD, scleroderma) | Both CTD and PAH documented; CTD-associated PAH classified as Group 1' | I27.21 + M34.x or other CTD code |
| Right heart catheterization showing mPAP ≥20 mmHg | Result in notes/procedure report; RHC is gold standard for PH diagnosis per Nice 2018 guidelines | I27.0–I27.29 depending on group + Z80.41/Z79 as applicable |
| Cor pulmonale documented | Distinguish chronic (I27.81) from acute cor pulmonale (I26.01–I26.09, PE-related); chronic = from chronic lung disease | I27.81 (chronic) or I26.0x (acute PE) |
| CTEPH (Group 4 PH) | History of PE + chronic thromboembolic obstruction; treated with pulmonary endarterectomy, riociguat, or balloon pulmonary angioplasty | I27.24 + I27.82 (chronic PE) |
| PPHN (newborn) | Neonatal diagnosis; high pulmonary vascular resistance; failure of normal circulatory transition at birth | P29.3 |
| Pregnancy with pre-existing HTN | HTN diagnosed BEFORE pregnancy or ≤20 weeks gestation | O10.x (NOT I10 during pregnancy) |
When a patient has documented hypertension AND a cardiac finding (left ventricular hypertrophy, diastolic dysfunction, systolic heart failure), the medical record should specify the relationship. If the provider's documentation does not clearly link the conditions, a compliant CDI query may ask: "Based on the documented findings of [hypertension] and [diastolic dysfunction/systolic heart failure/LVH], is there a causal relationship? If yes, is this hypertensive heart disease with or without heart failure? If heart failure is present, please specify type (systolic/diastolic/combined) and acuity (acute/chronic/acute-on-chronic)." Follow ACDIS/AHIMA query guidelines — queries must be non-leading with multiple choice options including clinical indicators.
🦴 Anatomy & Pathophysiology
Systemic Hypertension
Essential hypertension results from a complex interplay of genetic predisposition and environmental factors that increase systemic vascular resistance (SVR). The renin-angiotensin-aldosterone system (RAAS) plays a central role — angiotensin II causes direct vasoconstriction and stimulates aldosterone release, increasing sodium and water retention. Sympathetic nervous system overactivation, endothelial dysfunction, and impaired nitric oxide bioavailability compound the elevated BP.
End-organ damage pathways:
- Heart: Pressure overload causes left ventricular hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved EF (HFpEF). Chronic pressure overload may eventually cause systolic dysfunction (HFrEF). The coronary microcirculation also sustains injury, increasing ischemic risk.
- Kidneys: Hypertension causes glomerular hypertension, progressive nephrosclerosis, and podocyte damage → proteinuria → CKD. Per ICD-10-CM Guidelines I.C.9.a.2, the relationship between HTN and CKD is always assumed causal without explicit documentation.
- Brain: Small vessel disease, lacunar infarcts, cerebral microbleeds, and in HTN emergency, cerebral autoregulation failure → hypertensive encephalopathy (I67.4).
- Retina: Arteriovenous nicking, copper-wiring, flame hemorrhages, papilledema (grade IV) — coded as H35.0 with I10 as mandatory "code first" code.
- Aorta: Chronic pressure stress contributes to aortic dissection (I71.x) and aneurysm formation.
Pulmonary Hypertension
In PAH (Group 1), vasoconstriction, smooth muscle proliferation, endothelial dysfunction, and thrombosis in situ narrow the pulmonary arterioles, raising pulmonary vascular resistance (PVR). The right ventricle (RV) initially adapts via hypertrophy, but eventually fails — manifesting as cor pulmonale (I27.81). Key vasoactive imbalances: reduced prostacyclin (vasodilator), reduced nitric oxide, elevated endothelin-1 (potent vasoconstrictor and proliferative agent). Targeted PAH therapies address these pathways (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, soluble guanylate cyclase stimulators).
In Groups 2–5, the mechanism differs by etiology: Group 2 PH occurs from elevated pulmonary venous pressure transmitted backward from left-sided cardiac disease; Group 3 from chronic hypoxic vasoconstriction; Group 4 from mechanical obstruction of pulmonary vessels by organized thrombus; Group 5 from miscellaneous mechanisms including extrinsic compression or metabolic derangements.
💊 Medication Impact / Treatment
Antihypertensive Medication Classes (Systemic HTN)
Chronic antihypertensive pharmacotherapy should be documented in the medical record and may be flagged with long-term drug use code Z79.899 (Other long-term drug use). Key classes:
- ACE inhibitors / ARBs — first-line for HTN with CKD/proteinuria and hypertensive HF; renal-protective. E.g., lisinopril, enalapril (ACEi); losartan, valsartan (ARB). ARNI (sacubitril/valsartan) for HFrEF.
- Thiazide / thiazide-like diuretics — hydrochlorothiazide, chlorthalidone; first-line in many guidelines.
- Calcium channel blockers (CCB) — amlodipine; first-line; especially for older adults and isolated systolic HTN.
- Beta-blockers — metoprolol succinate, carvedilol; preferred with hypertensive heart disease/HF; atenolol for rate control.
- Aldosterone antagonists — spironolactone, eplerenone; used in resistant HTN and primary aldosteronism (I15.2).
- Loop diuretics — furosemide (J1940), bumetanide; for volume overload with HTN + HF or CKD stage 4-5.
- Alpha-1 blockers, central agonists (clonidine), direct vasodilators (hydralazine) — adjunctive.
- IV antihypertensives for HTN emergency — nicardipine, labetalol, clevidipine, esmolol, nitroprusside; coded per IV drug administration.
- Epoetin alfa in ESRD — Q4081 (HCPCS); secondary polycythemia can contribute to elevated BP.
PAH-Specific Therapies
PAH requires specialized treatments targeting the pathobiological pathways. Oral agents are generally covered under Medicare Part D; IV/SC/inhaled agents may be covered under Part B or DME:
- Endothelin receptor antagonists (ERAs) — bosentan (Tracleer), ambrisentan (Letairis), macitentan (Opsumit); oral — Part D. Require REMS programs due to hepatotoxicity/teratogenicity risk.
- PDE-5 inhibitors — sildenafil (Revatio), tadalafil (Adcirca); oral — Part D.
- Soluble guanylate cyclase (sGC) stimulators — riociguat (Adempas); oral — Part D. CONTRAINDICATED with PDE-5 inhibitors.
- Prostacyclin analogues / pathway agonists:
- Epoprostenol (Flolan, Veletri) IV continuous — J3490 or billed under ambulatory infusion pump E0781; Part B DME pump
- Treprostinil SC/IV (Remodulin) — J3490; inhaled (Tyvaso) — J3490 or Part B nebulizer
- Iloprost inhaled (Ventavis) — J3490
- Selexipag (Uptravi) — oral prostacyclin receptor agonist; Part D.
Documentation of specific PAH therapy should prompt CDI review to ensure appropriate PAH group coding (I27.0, I27.21–I27.29) and confirmation that right heart catheterization values are captured in the record.
Riociguat (Adempas) and PDE-5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated together due to risk of severe hypotension. When auditing medication records in PAH patients, flag concurrent use for physician review. This is a black-box warning from the FDA.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT procedure coding, HCC v28 risk adjustment mapping, CDI query templates, MS-DRG impact, and a complete audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
🔒 Register or sign in to read the full guide
Unlock the full guide including:
- • 📘 ICD-10-CM Guidelines (FY2026)
- • 🔢 ICD-10-CM Code Set (FY2026)
- • 🔎 Indexing
- • 🏥 CPT (2026)
- • 🧾 HCPCS (2026)
- • 📚 AHA Coding Clinic (Recent Guidance)
- • 💰 HCC / Risk Adjustment (v28)
- • ✍️ CDI Query Templates
- • 🧑⚕️ Treatments (Clinical)
- • 🎓 Patient Education / Summary
